LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Independent Study Shows Significant Decline in Cardiac Device Infections with TYRX® Antibacterial Envelope
New Data in High Risk Patients Presented at Heart Rhythm Society
Shows a 70% Reduction in CIED Infections
Denver, CO (May 10, 2013): Use of TYRX, Inc.’s AIGISRx® Antibacterial Envelope significantly reduced device infection rates in patients at high risk for device infection who received cardiovascular implantable electronic device (CIED) implants, according to a study presented today at Heart Rhythm 2013, the Heart Rhythm Society’s 34th Annual Scientific Sessions.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.